Glomeruloid Microvascular Proliferation and Breast Cancer Outcomes
Author Information
Author(s): J R Goffin, O Straume, P O Chappuis, J-S Brunet, L R Bégin, N Hamel, N Wong, L A Akslen, W D Foulkes
Primary Institution: McGill University
Hypothesis
Is glomeruloid microvascular proliferation associated with p53 expression, BRCA1 mutations, and breast cancer outcomes?
Conclusion
The presence of glomeruloid microvascular proliferation is linked to worse survival outcomes in breast cancer patients, particularly those with BRCA1 mutations.
Supporting Evidence
- 43 breast cancers (17%) had glomeruloid microvascular proliferation.
- Presence of GMP was associated with higher nuclear grade and p53 positivity.
- 50.3% of women with GMP died of breast cancer at 10 years compared to 25.7% without GMP.
Takeaway
This study found that a specific type of blood vessel growth in breast cancer can mean a higher chance of dying from the disease, especially for women with certain genetic mutations.
Methodology
The study assessed 292 Ashkenazi Jewish women with breast cancer, evaluating tissue samples for glomeruloid microvascular proliferation and correlating findings with clinical outcomes.
Potential Biases
Potential bias in sample selection and retrospective analysis.
Limitations
The study is limited to a specific population (Ashkenazi Jewish women) and may not be generalizable to other groups.
Participant Demographics
Ashkenazi Jewish women aged 65 years or less with primary nonmetastatic breast cancer.
Statistical Information
P-Value
0.0003
Confidence Interval
95% CI: 1.2–3.0
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website